These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 11504824

  • 1. Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: a randomized, double-blind, placebo-controlled trial.
    Drenth JP, Vonk AG, Simon A, Powell R, van der Meer JW.
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1221-6. PubMed ID: 11504824
    [Abstract] [Full Text] [Related]

  • 2. Unstimulated peripheral blood mononuclear cells from patients with the hyper-IgD syndrome produce cytokines capable of potent induction of C-reactive protein and serum amyloid A in Hep3B cells.
    Drenth JP, van der Meer JW, Kushner I.
    J Immunol; 1996 Jul 01; 157(1):400-4. PubMed ID: 8683144
    [Abstract] [Full Text] [Related]

  • 3. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group.
    Drenth JP, Cuisset L, Grateau G, Vasseur C, van de Velde-Visser SD, de Jong JG, Beckmann JS, van der Meer JW, Delpech M.
    Nat Genet; 1999 Jun 01; 22(2):178-81. PubMed ID: 10369262
    [Abstract] [Full Text] [Related]

  • 4. Serum amyloid A serum concentrations and genotype do not explain low incidence of amyloidosis in Hyper-IgD syndrome.
    van der Hilst JC, Drenth JP, Bodar EJ, Bijzet J, van der Meer JW, Simon A, International HIDS Study Group.
    Amyloid; 2005 Jun 01; 12(2):115-9. PubMed ID: 16011988
    [Abstract] [Full Text] [Related]

  • 5. Thalidomide suppressed interleukin-6 but not tumor necrosis factor-alpha in volunteers with experimental endotoxemia.
    Shannon E, Noveck R, Sandoval F, Kamath B, Kearney M.
    Transl Res; 2007 Nov 01; 150(5):275-80. PubMed ID: 17964516
    [Abstract] [Full Text] [Related]

  • 6. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome.
    Simon A, Drewe E, van der Meer JW, Powell RJ, Kelley RI, Stalenhoef AF, Drenth JP.
    Clin Pharmacol Ther; 2004 May 01; 75(5):476-83. PubMed ID: 15116060
    [Abstract] [Full Text] [Related]

  • 7. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease.
    Mansfield JC, Parkes M, Hawthorne AB, Forbes A, Probert CS, Perowne RC, Cooper A, Zeldis JB, Manning DC, Hawkey CJ.
    Aliment Pharmacol Ther; 2007 Aug 01; 26(3):421-30. PubMed ID: 17635377
    [Abstract] [Full Text] [Related]

  • 8. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model.
    Bodar EJ, van der Hilst JC, Drenth JP, van der Meer JW, Simon A.
    Neth J Med; 2005 Aug 01; 63(7):260-4. PubMed ID: 16093577
    [Abstract] [Full Text] [Related]

  • 9. [Hyper-IgD syndrome (HIDS)].
    Scolozzi R.
    Recenti Prog Med; 1995 Jun 01; 86(6):243-7. PubMed ID: 7624586
    [Abstract] [Full Text] [Related]

  • 10. Aspirin compared with acetaminophen in the treatment of fever and other symptoms of upper respiratory tract infection in adults: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-dose, 6-hour dose-ranging study.
    Bachert C, Chuchalin AG, Eisebitt R, Netayzhenko VZ, Voelker M.
    Clin Ther; 2005 Jul 01; 27(7):993-1003. PubMed ID: 16154478
    [Abstract] [Full Text] [Related]

  • 11. A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma.
    Brenne AT, Romstad LH, Gimsing P, Juliusson G, Turesson I, Romundstad P, Borset M, Sundan A, Waage A.
    Haematologica; 2004 May 01; 89(5):552-6. PubMed ID: 15136218
    [Abstract] [Full Text] [Related]

  • 12. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
    Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J.
    Arthritis Rheum; 2003 Jun 01; 48(6):1667-75. PubMed ID: 12794835
    [Abstract] [Full Text] [Related]

  • 13. A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum.
    Villahermosa LG, Fajardo TT, Abalos RM, Balagon MV, Tan EV, Cellona RV, Palmer JP, Wittes J, Thomas SD, Kook KA, Walsh GP, Walsh DS.
    Am J Trop Med Hyg; 2005 May 01; 72(5):518-26. PubMed ID: 15891124
    [Abstract] [Full Text] [Related]

  • 14. Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome.
    Drenth JP, van Deuren M, van der Ven-Jongekrijg J, Schalkwijk CG, van der Meer JW.
    Blood; 1995 Jun 15; 85(12):3586-93. PubMed ID: 7780142
    [Abstract] [Full Text] [Related]

  • 15. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, Fox L, Chernoff M, Wu AW, MacPhail LA, Vasquez GJ, Wohl DA.
    N Engl J Med; 1997 May 22; 336(21):1487-93. PubMed ID: 9154767
    [Abstract] [Full Text] [Related]

  • 16. Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers.
    Jacobson JM, Greenspan JS, Spritzler J, Fox L, Fahey JL, Jackson JB, Chernoff M, Wohl DA, Pulvirenti JJ, Hooton TM, Shikuma C.
    J Infect Dis; 2001 Jan 15; 183(2):343-346. PubMed ID: 11120935
    [Abstract] [Full Text] [Related]

  • 17. Effect of inflammatory attacks in the classical type hyper-IgD syndrome on immunoglobulin D, cholesterol and parameters of the acute phase response.
    Simon A, Bijzet J, Voorbij HA, Mantovani A, van der Meer JW, Drenth JP.
    J Intern Med; 2004 Sep 15; 256(3):247-53. PubMed ID: 15324368
    [Abstract] [Full Text] [Related]

  • 18. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome.
    Takada K, Aksentijevich I, Mahadevan V, Dean JA, Kelley RI, Kastner DL.
    Arthritis Rheum; 2003 Sep 15; 48(9):2645-51. PubMed ID: 13130485
    [Abstract] [Full Text] [Related]

  • 19. Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: a double-blind placebo-controlled clinical trial.
    Ramirez-Amador VA, Esquivel-Pedraza L, Ponce-de-Leon S, Reyes-Teran G, Gonzalez-Guevara M, Ponce-de-Leon S, Sierra-Madero JG.
    Clin Infect Dis; 1999 Apr 15; 28(4):892-4. PubMed ID: 10825055
    [Abstract] [Full Text] [Related]

  • 20. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis.
    Revuz J, Guillaume JC, Janier M, Hans P, Marchand C, Souteyrand P, Bonnetblanc JM, Claudy A, Dallac S, Klene C.
    Arch Dermatol; 1990 Jul 15; 126(7):923-7. PubMed ID: 2193629
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.